Skip to main content

Request your Emgality loading dose kit sample, delivered to your officea

The loading dose kit (sample) lets you provide patients living with migraine a chance to try out administering the first monthly dose of Emgality (2 injections of 120 mg each) right in your office. After that, patients can inject 1 dose, or injection, on their own each month. Loading dose kits (samples) are intended to assess tolerability and efficacy for individual patients in the office.

To request your loading dose kit samples and/or demonstration pen*, use the link below to check eligibility. If eligible, you will be directed to complete and submit your request electronically. Approved samples requests will be delivered to your office.

*Demonstration Pen: For demonstration and training only. Not for patients or injection into humans. Does not contain medicine. Only to be used by a healthcare professional. Needles are not included.

aSamples are not available for episodic cluster headache.

SELECT IMPORTANT SAFETY INFORMATION

Contraindications

Emgality is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients.

IMPORTANT SAFETY INFORMATION

Emgality is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients.

Hypersensitivity reactions, including dyspnea, urticaria, and rash, have occurred with Emgality in clinical studies and the postmarketing setting. Cases of anaphylaxis and angioedema have also been reported in the postmarketing setting. If a serious or severe hypersensitivity reaction occurs, discontinue administration of Emgality and initiate appropriate therapy. Hypersensitivity reactions can occur days after administration and may be prolonged.

The most common adverse reactions (incidence ≥2% and at least 2% greater than placebo) in Emgality clinical studies were injection site reactions.

Please see Full Prescribing Information, including Patient Information, for Emgality. See Instructions for Use included with the device.

GZ HCP ISI 14SEP2022

INDICATIONS

Emgality is a calcitonin gene-related peptide (CGRP) antagonist indicated in adults for the:

  • Preventive treatment of migraine
  • Treatment of episodic cluster headache